Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.59 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formetorex SCHEMBL1812509 | 1.00 | TAAR1 (1.00) | TAAR1MEN1KMT2AEPHX1SIGMAR1 | |
| Formetorex SCHEMBL2780459 | 1.00 | TAAR1 (1.00) | TAAR1MEN1KMT2AEPHX1SIGMAR1 | |
| SCHEMBL8763948 | 0.90 | TAAR1 (0.81) | TAAR1MEN1KMT2AEPHX1SIGMAR1 | |
| SCHEMBL10439420 | 0.82 | KMT2A (0.70) | TAAR1MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL10439384 | 0.82 | KMT2A (0.70) | TAAR1MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL14944821 | 0.82 | KMT2A (0.70) | TAAR1MEN1KMT2AEPHX1NPC1 | |
| SCHEMBL8763940 | 0.82 | TAAR1 (0.69) | TAAR1MEN1KMT2AEPHX1SIGMAR1 | |
| SCHEMBL11077995 | 0.81 | TAAR1 (0.68) | TAAR1MEN1KMT2AEPHX1SIGMAR1 | |
| SCHEMBL12280099 | 0.81 | KMT2A (0.68) | TAAR1MEN1KMT2AEPHX1SIGMAR1 | |
| SCHEMBL11294468 | 0.81 | TAAR1 (0.68) | TAAR1MEN1KMT2AEPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017098533-A2 | PROCESS FOR PREPARATION OF LISDEXAMPHETAMINE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-15 | — | — | WO | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | TAAR1 3873/4885MEN1 3013/4885KMT2A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.